| Literature DB >> 29597315 |
Fan Leng1, Fang Liu2, Yongtao Yang3, Yu Wu4, Weiqun Tian5.
Abstract
The emergence of nanomedicine has enriched the knowledge and strategies of treating diseases, and especially some incurable diseases, such as cancers, acquired immune deficiency syndrome (AIDS), and neurodegenerative diseases. The application of nanoparticles in medicine is in the core of nanomedicine. Nanoparticles can be used in drug delivery for improving the uptake of poorly soluble drugs, targeted delivery to a specific site, and drug bioavailability. Early diagnosis of and targeted therapies for cancers can significantly improve patients' quality of life and extend patients' lives. The advantages of nanoparticles have given them a progressively important role in the nanodiagnosis and nanotherapy of common cancers. To provide a reference for the further application of nanoparticles, this review focuses on the recent development and application of nanoparticles in the early diagnosis and treatment of the three common cancers (lung cancer, liver cancer, and breast cancer) by using quantum dots, magnetic nanoparticles, and gold nanoparticles.Entities:
Keywords: common cancers; nanodiagnostics; nanoparticles; nanotherapies
Year: 2018 PMID: 29597315 PMCID: PMC5923532 DOI: 10.3390/nano8040202
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1The top five ranking of the most common cancer deaths across the world from the World Health Organization’s report in 2015 [1].
Common cell lines of the three cancers from preclinical research.
| Cancer | Cell Lines | Biomarkers | Tumorigenic | Nanoplatform | Refrence |
|---|---|---|---|---|---|
| Breast | MCF-7 | ER, PR | Nude mice | QDs | [ |
| MDA-MB-231 | CD44 HA receptor | Nude mice | SPIONs | [ | |
| T-47D | ER, PR | Nude mice | - | [ | |
| SK-BR-3 | HER2 | Nude mice | IONPs | [ | |
| Lung | A549 | CD90, HPRT | Nude mice | - | [ |
| NCI-H460 | HPRT | Nude mice | IONPs | [ | |
| SK-MES-1 | CD24 | Nude mice | - | [ | |
| Liver | Hep G2 | CD90, CD44 | - | - | - |
| Huh7 | CD133 | Mice | - | [ |
ER, estrogen receptor; PR, progesterone receptor; HA, hyaluronan; HPRT, hypoxanthine-guanine phosphoribosyltransferase; IONPs, iron-oxide nanoparticles; SPIONs, superparamagnetic iron-oxide nanoparticles; QDs, quantum dots.
Figure 2Schematic diagrams of a drug-loaded magnetic nanoparticle (MNP) with tumor targeting, hyperthermia, and long-term circulation. AMF: alternating magnetic field; PMF: permanent magnetic field.
Targeted drug therapies that have been approved by the U.S. Food and Drug Administration. Data from the National Cancer Institute [77].
| Cancer | Targeted Drug Therapies | Molar Mass (g/mol) | Chemical Formula | Target |
|---|---|---|---|---|
| Breast | Everolimus (Afinitor®) | 958.224 | C53H83NO14 | - |
| Toremifene (Fareston®) | 405.959 | C26H28ClNO | - | |
| Trastuzumab (Herceptin®) * | 145,531.5 | C6470H10012N1726O2013S42 | HER2/neu | |
| Anastrozole (Arimidex®) | 293.366 | C17H19N5 | - | |
| Lapatinib (Tykerb®) | 581.058 | C29H26ClFN4O4S | - | |
| Lung | Bevacizumab (Avastin®) * | 149,196.82 | C6638H10160N1720O2108S44 | VEGF-A |
| Crizotinib (Xalkori®) | 450.337 | C21H22Cl2FN5O | - | |
| Erlotinib (Tarceva®) | 393.436 | C22H23N3O4 | - | |
| Nivolumab (Opdivo®) * | 143,600 | C6362H9862N1712O1995S42 | PD-1 | |
| Liver | Sorafenib (Nexavar®) | 464.825 | C21H16ClF3N4O3 | - |
| Regorafenib (Stivarga®) | 482.82 | C21H17ClF4N4O4 | - |
* Monoclonal antibody.
Scheme 1Schematic representation of assemblies composed by poly (ε-caprolactone) and hydrophilic poly 2-(2-methoxyethoxy) ethyl methacrylate-grafted Au nanoparticles (AuNPs) and their potential application in photothermal therapy and computed tomography (CT) imaging of cancer. Reproduced with permission [92], Ivyspring International Publisher, 2014. NIR: near infrared.